Table 1.
Baseline characteristics
| Characteristics | HETROM-2.5, n = 168 | HETROM-5, n = 171 | Placebo, n = 85 |
|---|---|---|---|
| Age, median (range), years | 38 (19–70) | 41 (18–74) | 42 (18–71) |
| Age, n (%) | |||
| 18–65 years | 162 (96.4) | 163 (95.3) | 82 (96.5) |
| > 65 years | 6 (3.6) | 8 (4.7) | 3 (3.5) |
| Height, median (range), cm | 162.5 (147.0–182.0) | 161.0 (147.0–182.0) | 162.0 (150.0–185.5) |
| Weight, median (range), kg | 61.0 (39.0–115.0) | 62.5 (43.5–110.0) | 63.0 (44.5–88.0) |
| BMI, median (range), kg/m2 | 23.4 (16.9–37.6) | 24.4 (17.3–35.9) | 23.6 (18.0–30.5) |
| Female, n (%) | 122 (72.6) | 119 (69.6) | 60 (70.6) |
| Time since first ITP diagnosis, n (%) | |||
| 0.5–1 year | 32 (19.0) | 35 (20.5) | 13 (15.3) |
| 1–3 years | 53 (31.5) | 56 (32.7) | 19 (22.4) |
| 3–5 years | 31 (18.5) | 16 (9.4) | 14 (16.5) |
| ≥ 5 years | 52 (31.0) | 64 (37.4) | 39 (45.9) |
| Prior splenectomy, n (%) | 14 (8.3) | 15 (8.8) | 4 (4.7) |
| Bleeding (WHO bleeding scale grade 1–4), n (%) | 108 (64.3) | 93 (54.4) | 52 (61.2) |
| Concomitant ITP medication at baseline, n (%) | 168 (100.0) | 168 (98.2) | 83 (97.6) |
| Baseline platelet count, median (range), × 109/L | 13 (1–29) | 13 (2–29) | 13 (1–29) |
| Baseline platelet count, n (%) | |||
| < 10 × 109/L | 64 (38.1) | 58 (33.9) | 35 (41.2) |
| 10–30 × 109/L | 104 (61.9) | 113 (66.1) | 50 (58.8) |
HETROM-2.5, dosage was titrated from an initial dose of once-daily 2.5 mg hetrombopag; HETROM-5, dosage was titrated from an initial dose of once-daily 5 mg hetrombopag; BMI, body mass index; ITP, immune thrombocytopenia; WHO, World Health Organization